VCE-004.3   Click here for help

GtoPdb Ligand ID: 10030

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: VCE-004.3 is a semi-synthetic cannabidiol quinone derivative [2]. It acts as a dual PPARγ/CB2 receptor agonist and CB1 receptor modulator. The structure is claimed in patent WO2015158381 [1]. VCE-004.3 is functional (promotes transactivation) on PPARγ via a binding site that is distinct from the canonical rosiglitazone binding site on this nuclear receptor.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 11
Topological polar surface area 66.4
Molecular weight 413.29
XLogP 7.3
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCCCCNC1=C(CCCCC)C(=O)C(=O)C(=C1O)C1C=C(C)CCC1C(=C)C
Isomeric SMILES CCCCCNC1=C(CCCCC)C(=O)C(=O)C(=C1O)[C@@H]1C=C(C)CC[C@H]1C(=C)C
InChI InChI=1S/C26H39NO3/c1-6-8-10-12-20-23(27-15-11-9-7-2)25(29)22(26(30)24(20)28)21-16-18(5)13-14-19(21)17(3)4/h16,19,21,27,29H,3,6-15H2,1-2,4-5H3/t19-,21+/m0/s1
InChI Key CIEWIZBPWBLHSB-PZJWPPBQSA-N
References
1. Appendino G, Bellido Cabello De Alba ML, Munoz Blanco E, Illescas Taboada M. (2015)
NOVEL CANNABIDIOL QUINONE DERIVATIVES.
Patent number: WO2015158381. Assignee: VIVACELL BIOTECHNOLOGY ESPANA S.L.. Priority date: 16/04/2014. Publication date: 22/10/2015.
2. Del Rio C, Cantarero I, Palomares B, Gómez-Cañas M, Fernández-Ruiz J, Pavicic C, García-Martín A, Luz Bellido M, Ortega-Castro R, Pérez-Sánchez C et al.. (2018)
VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2 receptor-dependent pathways.
Br J Pharmacol, 175 (19): 3813-3831. [PMID:30033591]